The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy™ at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo (Novo Nordisk)
Diabetes News Service
The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy™ at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo (Novo Nordisk)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com